#CfRNA
Discover GeneLLM: a Transformer model decoding cancer signatures directly from cfRNA sequences. This novel approach enhances detection by skipping gene-level quantification. PMID:42425994, Nat Commun 2026, @NatureComms https://doi.org/10.1038/s41467-026-74411-3 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Decoding cancer circulating transcriptomic signatures with language models | Nature Communications
Current liquid biopsy methods for multi-cancer detection using plasma cell-free RNA (cfRNA, short RNA fragments circulating in blood that can reflect disease states) typically rely on gene annotations, which can overlook signals from unannotated or repetitive genomic regions. We present GeneLLM, a Transformer-based model that directly processes the nucleotide sequences of human-mapped cfRNA reads to identify cancer-indicative signatures. By bypassing gene-level quantification, the model retains signals from transcriptomic dark matter. The model learns latent pseudo-biomarkers (prototype representations from aggregated cfRNA read embeddings) that serve as discriminative features for cancer classification, rather than corresponding to explicit genomic sequences. Here we show that, in a multi-centre cohort, GeneLLM achieves ROC-AUC values ranging from 0.9250 to 0.9962 across several cancers, while maintaining comparable performance at one-sixth of the typical sequencing depth. These resul
doi.org
November 10, 2026 at 12:00 AM
We're at #AMP2026 in Seattle this week, kicking things off with our Corporate Workshop session at 10 am in Tahoma 3! Hear from NEB Dev Scientists Maggie and Anagha on their latest work. "One Sample, Many Insights: Multiomic Profiling in cfDNA and cfRNA Samples"
November 11, 2026 at 5:00 PM
Urine cfRNA profiling accurately detects bladder cancer and predicts treatment responses, offering a novel, noninvasive diagnostic avenue.

by Liu KJ, Shi WY (...) Diehn M et 39 al. in Nat Med #MedSky

👉 get more here

📖 read the article:
Urine cell-free RNA for bladder cancer detection and treatment response prediction - Nature Medicine
Applied to samples from more than 600 patients and controls, urinary cell-free RNA profiling with uRARE-seq demonstrated high sensitivity in detecting bladder cancer, and correlated with treatment response.
www.nature.com
October 11, 2026 at 6:52 PM
Resero Bio's Innovative Platform Revolutionizes Bladder Cancer Detection and Treatment Predictions#USA#Bladder_Cancer#San_Carlos#Resero_Bio#cfRNA_platform
Resero Bio's Innovative Platform Revolutionizes Bladder Cancer Detection and Treatment Predictions
Resero Bio's new study showcases its cfRNA platform's ability to detect bladder cancer and predict treatment responses non-invasively, marking a significant advancement in precision diagnostics.
third-news.com
October 5, 2026 at 11:12 AM
Urine cell-free RNA for bladder cancer detection and treatment response prediction
In contrast to RNA from cellular urinary sediments, cfRNA from urinary supernatants is highly fragmented (Extended Data Fig. 1a), suggesting that a sequencing approach optimized for short RNA fragments would be required. We therefore adapted RARE-Seq8, a hybrid capture-based sequencing approach for plasma cfRNA, to analyze urine cfRNA. We compared three extraction strategies and found that a silica column-based approach yielded the highest RNA concentrations (Extended Data Fig. 1b). Urine specific gravity was significantly correlated with RNA yield (R = 0.5, P = 0.0004; Extended Data Fig. 1c), but did not impact gene expression profiles (Extended Data Fig. 1d). RNA yield was inversely associated with urine pH, consistent with lower RNA stability under alkaline conditions (P = 0.002; Extended Data Fig. 1e) but unaffected by storage time at −80 °C (R = −0.0075, P = 0.85; Extended Data Fig. 1f). Two preservative strategies (ethylenediaminetetraacetic acid or a commercial preservative solution) yielded similar RNA concentrations, fragment sizes and gene expression profiles (P = 0.66; Extended Data Fig. 1g,h and Supplementary Table 1). In addition, we observed no significant changes in RNA concentration or transcript abundances after one freeze–thaw cycle (Extended Data Fig. 1i,j). Lastly, to test the stability of urine cfRNA,...
www.nature.com
October 2, 2026 at 9:14 PM
Is the RNA in our blood just fragile debris, or a readable record of how the body responds to disease? 🧬🩸 In our new Opinion in @cp-trendsbiochem.bsky.social, we propose a framework for cfRNA fragmentomics.
October 2, 2026 at 12:48 AM
Microbiome Cell-Free RNA Differentiates Colorectal Most Cancers

Within the ongoing quest to revolutionize most cancers diagnostics, circulating cell-free RNA (cfRNA) has emerged as a potent organic reservoir, providing unprecedented glimpses into the molecular underpinnings of malignancy. Just…
Microbiome Cell-Free RNA Differentiates Colorectal Most Cancers
Within the ongoing quest to revolutionize most cancers diagnostics, circulating cell-free RNA (cfRNA) has emerged as a potent organic reservoir, providing unprecedented glimpses into the molecular underpinnings of malignancy. Just lately, a groundbreaking examine has unveiled a complicated sequencing method that delves deep into the chemical modifications of cfRNA current in plasma, illuminating a novel pathway for the early detection of colorectal most cancers.
nextbusiness24.com
July 8, 2025 at 12:39 PM
What are the real needs and priorities of expectant families? 🤰👨‍👨‍👦‍👦 Please help us shape a future study by watching our webinar and participating in our survey!
Find all info here: sung.github.io/cfRNA-PPIE/
#pregnancy #whum #preeclampsia #FGR
November 20, 2025 at 10:49 AM


A Biologically Grounded Structural Causal Model Enables cfRNA Specific In-Context Learning

https://www.biorxiv.org/content/10.64898/2025.12.10.693604v1
December 15, 2025 at 1:36 PM
"These findings highlight the potential of circulating cfRNA to advance biomarker discovery and uncover disease mechanisms for ME/CFS."
Das widerspricht sich einfach nicht.
Es ist nicht das smoking gun.
August 11, 2025 at 8:36 PM
7/10. And where it matters most, early stage. The platform reached 73.7% pooled sensitivity for Stage I–II disease at 90% specificity, exactly where DNA-based assays tend to struggle. cfRNA looks like a genuine orthogonal layer to cfDNA.
July 16, 2026 at 10:46 AM
5/10. We tamed the technical noise. A double-DNase protocol plus RUVg normalization stripped out platelet-driven “unwanted variation”, the single biggest confounder in cfRNA-seq. Clean signal in, better model out.
July 16, 2026 at 10:46 AM
4/10. It’s real biology, not noise. The genes we found differentially expressed light up hallmark CRC processes: inflammation, EMT, hypoxia, coagulation, and the Warburg effect (glycolysis up, oxidative phosphorylation down). cfRNA is reading tumour biology from a blood draw.
July 16, 2026 at 10:46 AM
3/10. So we built an optimized, end-to-end cfRNA platform and applied it to 505 plasma samples (255 healthy controls + 250 CRC patients) from Spanish biobanks, one standardized protocol, one uniform bioinformatics pipeline.
July 16, 2026 at 10:46 AM
July 15, 2025 at 8:56 AM
And now for a not-so-humble brag…
We were thrilled when the analysis revealed our own in-house Flomics libraries, using a rigorous double-DNase digestion protocol, ranked as the highest-quality dataset among all whole-cfRNA-Seq methods! 🎉💪
July 15, 2025 at 8:39 AM
Fresh insights from the Flomics team! 🧬💻

Our new preprint is out:
“Systematic cross-study assessment of RNA-Seq workflows for plasma cfRNA profiling”
Is cfRNA the wild west of protocols? We investigated.

📄 Read it: www.biorxiv.org/cgi/content/...
Systematic cross-study assessment of RNA-Seq experimental workflows for plasma cell-free transcriptome profiling
Plasma cell-free RNA (cfRNA) is a promising source of non-invasive biomarkers, but its clinical translation is hindered by technical challenges and a lack of protocol standardization, which compromise...
www.biorxiv.org
July 15, 2025 at 8:39 AM
A Biologically Grounded Structural Causal Model Enables cfRNA Specific In-Context Learning https://www.biorxiv.org/content/10.64898/2025.12.10.693604v1
December 14, 2025 at 1:31 AM
Direct RNAseq still requires tens of nanograms of input (down from a full 1ug a couple years back) so it’s hard to believe this is practical for cfRNA unless pooled & tagged
November 25, 2023 at 7:33 PM
This is a cool paper. The one huge clanger for me was the “surprising” finding that most cfRNA is from leukocytes. That’s exactly what you usually see unless a subject is having massive organ failures
November 25, 2023 at 7:31 PM
"We can never do enough early collaboration.” 🤝
At #PMWC26, IDT President Ajay Gannerkote shared that early partnership is essential to accelerating innovations in #MRD. The panel explored how breakthroughs in cfDNA and cfRNA profiling are reshaping MRD, and transforming the future of oncology.
March 5, 2026 at 3:21 PM
We’ve made it to #PMWC26! Attendees—remember to:

👉Stop by booth #B722 to speak with IDT experts about how we’re powering over 80% of the MRD research market.
👉Attend IDT President Ajay Gannerkote’s panel on advancing MRD detection through cfDNA and cfRNA profiling (today, March 4, 11:00 a.m.).
March 4, 2026 at 5:06 PM
Ajay Gannerkote will be speaking about advancing #MRD detection through cfDNA and cfRNA profiling at #PMWC26!

Join Ajay’s panel to explore how cfDNA and cfRNA profiling are helping to advance MRD detection and reshape the future of cancer care.

Learn more: pmwcintl.com/session/mar-...
February 26, 2026 at 9:17 PM